Stay Updated with the Latest Journey Medical Corporation DERM News in Real Time
Find DERM news now at Meyka AI. Stay informed with the latest Journey Medical Corporation stocks updates, including price news, market analysis, and expert insights.
Corus Entertainment Cuts More Jobs at Global News and Radio on August 21
Corus Entertainment confirms fresh layoffs at Global B.C., Global National, News 640, and talk radio. Q3 revenue fell 16% and the company posted a $36.5M net loss.
OpenAI’s iMessage Plugin Raises Privacy Stakes for Apple on August 21
OpenAI rolled out an Apple Messages plugin for ChatGPT on Mac that can read, search, and send texts. The feature raises privacy questions despite local processing claims and default approval gates.
Gold Price Today: MCX Gold Jumps to ₹1,60,250. Why Gold Is Rising as Dollar Weakens, Fed Bets Shift
MCX gold price rose 0.52% to ₹1,60,250 on August 21, 2026, supported by a weaker dollar and falling US yields. September silver futures declined 1.02% to ₹2,45,736 on the same session. Healthy spot market demand and positive global cues drove bullion higher today. Brent crude slipped 0.27% to $93.52 a barrel, adding further support to…
Japan Ends 45-Hour Overtime Cap in September, Allowing Up to 100 Hours Monthly
Japan ends blanket 45-hour overtime guidance in September, allowing companies with special clauses to permit up to 100 hours monthly. Labor inspectors will focus on worker health protections instead.
Moderna Soars 122% on Melanoma Vaccine Breakthrough, August 21
Moderna stock jumps 122% after announcing its personalized mRNA melanoma vaccine met Phase 3 trial goals. The vaccine reduced cancer recurrence and spread when combined with Merck’s Keytruda.
Hays Stock Rises 0.52% as Recruiter Cuts Dividend 65% Amid Hiring Slump
Hays stock edged up 0.52% on August 20, 2026, after the recruitment giant posted FY26 results. The company cut its total annual dividend by 65%, from 1.24 pence to 0.44 pence per share. Net fees fell as hiring activity stayed weak across Hays’ key markets. Investors focused on cost cuts and stabilizing margins rather than…
Moderna Soars 177% on Melanoma Vaccine Win; Merck Gains 12% on August 20
Moderna jumps 177% and Merck rises 12% after their mRNA cancer vaccine meets Phase 3 endpoints for melanoma. The combo reduced cancer recurrence and spread in over 1,100 patients.
Moderna Soars 177% After Melanoma Vaccine Clears Phase 3 Trial on August 20
Moderna stock jumped 177% after its melanoma vaccine met Phase 3 trial endpoints. The personalized mRNA therapy showed significant improvements over standard treatment in over 1,100 patients.
Moderna Soars 177% on Melanoma Vaccine Win; August 20 Update
Moderna jumped 177% to $174.38 after Phase 3 melanoma vaccine trial success with Merck. The mRNA therapy reduced recurrence risk and represents the first approved late-stage cancer vaccine.